



(12) Translation of  
European patent specification

(11) NO/EP 3114128 B1

NORWAY

(19) NO  
(51) Int Cl.  
*C07D 487/04 (2006.01)*  
*A61K 31/4985 (2006.01)*  
*A61P 31/12 (2006.01)*  
*C07D 498/04 (2006.01)*  
*C07D 513/04 (2006.01)*

**Norwegian Industrial Property Office**

---

(21) Translation Published 2019.05.13

(80) Date of The European Patent Office Publication of the Granted Patent 2019.01.02

(86) European Application Nr. 15710127.0

(86) European Filing Date 2015.03.04

(87) The European Application's Publication Date 2017.01.11

(30) Priority 2014.03.07, WO, PCT/CN14/073068  
2014.07.25, WO, PCT/CN14/083027  
2015.01.16, WO, PCT/CN15/070895

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Validation States: MA

(73) Proprietor F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits

(72) Inventor GUO, Lei, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
HU, Taishan, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
KOU, Buyu, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
LIN, Xianfeng, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
SHEN, Hong, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
SHI, Houguang, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
YAN, Shixiang, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
ZHANG, Weixing, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
ZHANG, Zhisen, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
ZHOU, Mingwei, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina  
ZHU, Wei, Building No. 5Lane 720 Cailun Road, Shanghai 201203, Kina

(74) Agent or Attorney PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

---


(54) Title **NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION**

(56) References  
Cited: WO-A1-2014/029193  
WO-A1-2014/184328  
DE-A1- 10 013 126

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**PATENTKRAV**

## 1. Forbindelse med formel (I)



hvor i

R<sup>1</sup> er hydrogen, halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen, hydroksyC<sub>1-6</sub>alkyl, aminokarbonyl, C<sub>1-6</sub>alkoksykarbonyl eller karboksy;

R<sup>6</sup> er hydrogen, C<sub>1-6</sub>alkoksykarbonyl eller karboksy-C<sub>m</sub>H<sub>2m-</sub>;

X er karbonyl eller sulfonyl;

Y er -CH<sub>2</sub>- , -O- eller -N(R<sup>7</sup>)-,

hvor i R<sup>7</sup> er hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m-</sub>,

C<sub>1-6</sub>alkoksykarbonyl-C<sub>m</sub>H<sub>2m-</sub>, -C<sub>t</sub>H<sub>2t</sub>-COOH, -haloC<sub>1-6</sub>alkyl-COOH,

-(C<sub>1-6</sub>alkoksy)C<sub>1-6</sub>alkyl-COOH, -C<sub>1-6</sub>alkyl-O-C<sub>1-6</sub>alkyl-COOH,

-C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m-</sub>-COOH, -C<sub>m</sub>H<sub>2m-</sub>-C<sub>3-7</sub>sykloalkyl-COOH, hydroksy-C<sub>t</sub>H<sub>2t</sub>-,

karboksylspiro[3.3]heptyl eller karboksyfenyl-C<sub>m</sub>H<sub>2m-</sub>,

karboksypyridinyl-C<sub>m</sub>H<sub>2m-</sub>;

W er -CH<sub>2</sub>- , -C(C<sub>1-6</sub>alkyl)<sub>2</sub>- , -O- eller karbonyl;

n er 0 eller 1;

m er 0-7;

t er 1-7;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

2. Forbindelse ifølge krav 1, hvori

R<sup>1</sup> er hydrogen, klor, brom eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen, klor eller fluor;

R<sup>4</sup> er methyl, etyl eller propyl;

R<sup>5</sup> er hydrogen, hydroksymetyl, aminokarbonyl, metoksykarbonyl eller karboksy;

R<sup>6</sup> er hydrogen, methyl-O-karbonyl eller karboksymetyl;

X er carbonyl eller sulfonyl;

Y er -CH<sub>2</sub>- , -O- , -N(R<sup>7</sup>)-,

hvor R<sup>7</sup> er hydrogen, methyl, difluoretyl, isopropyl, isobutyl, t-butyl, syklopropyl,

syklopropylmetyl, methyl-O-karbonylisopropyl, karboksyethyl, karboksydifluoretyl,

karboksypropyl, karboksybutyl, karboksy(gemdimetyl)metyl,

karboksy(gemdimetyl)etyl, karboksy(gemdimetyl)propyl,

karboksy(gemdimetyl)butyl, karboksy(metyl)etyl, karboksy(etyl)etyl,

karboksy(metoksy)etyl, karboksysyklobutyl, karboksysyklobutylmetyl,

karboksysyklopentyl, karboksysykloheksyl, karboksymetylisyklopropyl,

karboksysyklopropylmetyl, karboksysyklobutylmetyl, karboksyspiro[3.3]heptyl,

karboksymetoksyethyl, karboksymetoksypropyl, hydroksyethyl,

hydroksymetyl(gemdimetyl)butyl, hydroksy(gemdimetyl)etyl, karboksyfenyl,


karboksypyridinyl eller karboksyfenylmetyl;

W er -CH<sub>2</sub>- , -C(CH<sub>3</sub>)<sub>2</sub>- , -O- eller carbonyl;

n er 0 eller 1;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

3. Forbindelse med formel (IA) ifølge krav 1,



hyori

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

$R^5$  er hydrogen, hydroksyC<sub>1-6</sub>alkyl, aminokarbonyl, C<sub>1-6</sub>alkoksykarbonyl eller karboksy;

R<sup>6</sup> er hydrogen, C<sub>1-6</sub>alkoksykarbonyl eller karboksy-C<sub>m</sub>H<sub>2m-1</sub>;

Y er -N(R<sup>7</sup>)-,

hvori R<sup>7</sup> er hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m-1</sub>,

$$\text{C}_{1-6}\text{alkoksykarbonyl-C}_m\text{H}_{2m}-, \quad -\text{C}_t\text{H}_{2t}-\text{COOH}, \quad -\text{haloC}_{1-6}\text{alkyl-COOH},$$

$$-(C_{1-6}alkoxy)C_{1-6}alkyl-COOH,$$

$$-\text{C}_t\text{H}_{2t}-\text{COOH},$$

-haloC<sub>1-6</sub>alkyl-COOH,

$-C_{3-7}sykloalkyl-C_mH_{2m}-COOH$ ,  $-C_mH_{2m}-C_{3-7}sykloalkyl-COOH$ , hydroksy- $C_lH_{2l-1}$ ,

karboksySpiro[3.3]heptyl

eller

karboksyfenyl-C<sub>m</sub>H<sub>2m</sub>-,

karboksypyridinyl-C<sub>m</sub>H<sub>2m</sub>-;

W er -CH<sub>2</sub>- eller karbonyl;

m er 0-7;

ter 1-7;

eller farm

4. Forbindelse ifølge krav 1 eller 3 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvori

R<sup>1</sup> er klor, brom eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen, klor eller fluor;

R<sup>4</sup> er methyl, etyl eller propyl;

R<sup>5</sup> er hydrogen, hydroksymetyl, aminokarbonyl, metoksykarbonyl eller karboksy;

R<sup>6</sup> er hydrogen, methyl-O-karbonyl eller karboksymetyl;

Y er –N(R<sup>7</sup>)–,

hvori R<sup>7</sup> er hydrogen, methyl, difluoretyl, isopropyl, isobutyl, t-butyl, syklopropyl, syklopropylmetyl, methyl-O-karbonylisopropyl, karboksyethyl, karboksydifluoretyl,

karboksypropyl, karboksybutyl, karboksy(gemdimetyl)metyl,

karboksy(gemdimetyl)etyl, karboksy(gemdimetyl)propyl,

karboksy(gemdimetyl)butyl, karboksy(metyl)etyl, karboksy(etyl)etyl,

karboksy(metoksy)etyl, karboksysyklobutyl, karboksysyklobutylmetyl,

karbokssyklpentyl, karbokssyklheksyl, karboksymetolsyklopropyl,

karbokssyklopropylmetyl, karbokssyklobutylmetyl, karboksySpiro[3.3]heptyl,


karboksymetoksyethyl, karboksymetoksypropyl, hydroksyethyl,

hydroksymetyl(gemdimetyl)butyl, hydroksy(gemdimetyl)etyl, karboksyfenyl,

karboksypyridinyl eller karboksyfenylmetyl;

W er –CH<sub>2</sub>– eller carbonyl.

5. Forbindelse med formel (IAA) ifølge krav 1 eller 3,



hvor i

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen, aminokarbonyl eller karboksy;

R<sup>6</sup> er hydrogen;

R<sup>7</sup> er C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>sykloalkyl, C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m</sub>-, -C<sub>t</sub>H<sub>2t</sub>-COOH, -C<sub>m</sub>H<sub>2m</sub>-C<sub>3-7</sub>sykloalkyl-COOH eller karboksyfenyl;

m er 0-7;

t er 1-7;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

6. Forbindelse ifølge et hvilket som helst av kravene 1, 3 eller 5 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvor i

R<sup>1</sup> er klor eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen eller fluor;

R<sup>4</sup> er methyl eller etyl;

R<sup>5</sup> er hydrogen, aminokarbonyl eller karboksy;

R<sup>6</sup> er hydrogen;

R<sup>7</sup> er methyl, isopropyl, isobutyl, t-butyl, difluoretetyl, syklopropyl, syklopropylmetyl, karboksy(gemdimetyl)ethyl, karboksy(gemdimetyl)propyl, karboksysyklopropylmetyl, karboksysyklobutylmetyl eller karboksyfenyl.

7. Forbindelse ifølge krav 5 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvori

R<sup>1</sup> er klor eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen eller fluor;


R<sup>4</sup> er methyl eller etyl;

R<sup>5</sup> er hydrogen eller karboksy;

R<sup>6</sup> er hydrogen;

R<sup>7</sup> er methyl, isopropyl, t-butyl, syklopropyl, karboksy(gemdimetyl)ethyl, karboksy(gemdimetyl)propyl, karboksysyklopropylmetyl, karboksysyklobutylmetyl eller karboksyfenyl.

8. Forbindelse med formel (IB) ifølge krav 1,




hvori

R<sup>1</sup> er hydrogen eller halogen;  
R<sup>2</sup> er hydrogen eller halogen;  
R<sup>3</sup> er hydrogen eller halogen;  
R<sup>4</sup> er C<sub>1-6</sub>alkyl;  
R<sup>5</sup> er hydrogen;  
R<sup>6</sup> er hydrogen eller karboksymetyl;  
Y er –CH<sub>2</sub>– eller –O–;  
W er –CH<sub>2</sub>–, –C(C<sub>1-6</sub>alkyl)<sub>2</sub>– eller –O–;  
n er 0 eller 1;  
eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

9. Forbindelse ifølge krav 1 eller 7 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvor

R<sup>1</sup> er hydrogen, klor eller brom;  
R<sup>2</sup> er hydrogen eller fluor;  
R<sup>3</sup> er hydrogen eller fluor;  
R<sup>4</sup> er metyl eller etyl;  
R<sup>5</sup> er hydrogen;  
R<sup>6</sup> er hydrogen eller karboksymetyl;  
Y er –CH<sub>2</sub>– eller –O–;  
W er –CH<sub>2</sub>–, –C(CH<sub>3</sub>)<sub>2</sub>– eller –O–;  
n er 0 eller 1.

10. Forbindelse med formel (ID) ifølge krav 1,



hvor i

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen, aminokarbonyl eller karboksy;

R<sup>6</sup> er hydrogen eller C<sub>1-6</sub>alkoksikarbonyl

X er karbonyl;

Y er -O- eller -N(R<sup>7</sup>)- eller -CH<sub>2</sub>-,

hvor i R<sup>7</sup> er hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>sykloalkyl,

C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m</sub>-, -C<sub>t</sub>H<sub>2t</sub>-COOH-C<sub>m</sub>H<sub>2m</sub>-C<sub>3-7</sub>sykloalkyl-COOH,

hydroksy-C<sub>t</sub>H<sub>2t</sub>-, karboksylspiro[3.3]heptyl eller karboksyfenyl-C<sub>m</sub>H<sub>2m</sub>-;

m er 0-7;

t er 1-7;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

11. Forbindelse ifølge krav 1 eller 9 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvor i

R<sup>1</sup> er klor, brom eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen eller fluor;

R<sup>4</sup> er methyl, etyl eller propyl;


R<sup>5</sup> er hydrogen, aminokarbonyl eller karboksy;

R<sup>6</sup> er hydrogen eller methyl–O-karbonyl;

X er karbonyl;

Y er -O-, -N(R<sup>7</sup>)- eller -CH<sub>2</sub>-,

12. Forbindelse med formel (IE) ifølge krav 1,



hvor i

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen eller karboksy;

R<sup>6</sup> er hydrogen eller karboksy-C<sub>m</sub>H<sub>2m</sub>-;

Y er  $-O-$ ,  $-N(R^7)-$  eller  $-CH_2-$ ,  
 hvori  $R^7$  er  $C_{1-6}$ alkyl,  $C_{3-7}$ sykloalkyl,  $-C_tH_{2t}-COOH$ ,  $-C_{3-7}sykloalkyl-C_mH_{2m}-COOH$ ,  
 $-C_mH_{2m}-C_{3-7}sykloalkyl-COOH$ ,  $-(C_{1-6}alkoksy)C_{1-6}alkyl-COOH$ ,  
 $-C_{1-6}alkyl-O-C_{1-6}alkyl-COOH$ , karboksylspiro[3.3]heptyl eller  
 karboksyfenyl- $C_mH_{2m}-$ ;  
 W er  $-CH_2-$  eller  $-C(C_{1-6}alkyl)_2-$ ;  
 m er 0-7;  
 t er 1-7;  
 eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.


13. Forbindelse ifølge krav 1 eller 11 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvori

$R^1$  er klor eller methyl;  
 $R^2$  er hydrogen eller fluor;  
 $R^3$  er hydrogen eller fluor;  
 $R^4$  er methyl eller etyl;  
 $R^5$  er hydrogen eller karboksy;  
 $R^6$  er hydrogen eller karboksymetyl;

Y er  $-O-$ ,  $-N(R^7)-$  eller  $-CH_2-$ ,  
 hvori  $R^7$  er isopropyl, methyl, isobutyl, t-butyl, syklopropyl, karboksyethyl, karboksypropyl, karboksybutyl, karboksy(gemdimetyl)metyl, karboksy(gemdimetyl)etyl, karboksy(metyl)etyl, karboksysyklobutyl, karboksysyklopropylmetyl, karboksysyklopentyl, karboksysykloheksyl, karboksymetysyklopropyl, karboksy(gemdimetyl)propyl, karboksy(etyl)etyl, karboksy(metoksy)etyl, karboksysyklobutylmetyl, karboksyspiro[3.3]heptyl, karboksymetoksyethyl, karboksymetoksypropyl, karboksyfenylmetyl eller karboksyfenyl;

W er  $-CH_2-$  eller  $-C(CH_3)_2-$ .

14. Forbindelse med formel (IE) ifølge krav 1,



hvor i

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen eller karboksy;

R<sup>6</sup> er hydrogen eller karboksy-C<sub>m</sub>H<sub>2m-</sub>;

Y er -N(R<sup>7</sup>)-,

hvor R<sup>7</sup> er hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>sykloalkyl, -C<sub>t</sub>H<sub>2t</sub>-COOH,  
-C<sub>m</sub>H<sub>2m-</sub>C<sub>3-7</sub>sykloalkyl-COOH eller karboksyfenyl;

W er -CH<sub>2</sub>-;

m er 0-7;

t er 1-7;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

15. Forbindelse ifølge krav 1 eller 13 eller farmasøytisk akseptable salter, eller enantiomerer eller diastereomerer derav, hvor i

R<sup>1</sup> er klor eller methyl;

R<sup>2</sup> er hydrogen eller fluor;

R<sup>3</sup> er hydrogen eller fluor;

R<sup>4</sup> er methyl eller etyl;

R<sup>5</sup> er hydrogen eller karboksy;


R<sup>6</sup> er hydrogen eller karboksymetyl;

Y er  $-\text{N}(\text{R}^7)-$ ,

hvori R<sup>7</sup> er hydrogen, methyl, t-butyl, syklopropyl, karboksy(gemdimetyl)ethyl, karboksy(gemdimetyl)propyl, karboksy(metyl)ethyl, karboksysisyklopropylmetyl, karboksysisyklopentyl, karboksysisykloheksyl, karboksysisyklobutylmetyl eller karboksyfenyl;

W er  $-\text{CH}_2-$ .

16. Forbindelse med formel (IAA) ifølge krav 1,



hvor i

R<sup>1</sup> er halogen eller C<sub>1–6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1–6</sub>alkyl;

R<sup>5</sup> er hydrogen eller karboksy;

R<sup>6</sup> er hydrogen;


R<sup>7</sup> er C<sub>1–6</sub>alkyl, haloC<sub>1–6</sub>alkyl, C<sub>3–7</sub>sykloalkyl,  $-\text{C}_m\text{H}_{2m}-\text{COOH}$ ,

$-\text{C}_m\text{H}_{2m}-\text{C}_{3–7}\text{sykloalkyl}-\text{COOH}$  eller karboksyfenyl;

m er 1-6;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

17. Forbindelse med formel (IAB) ifølge krav 1,



hvor i

R<sup>1</sup> er halogen eller C<sub>1-6</sub>alkyl;

R<sup>2</sup> er hydrogen eller halogen;

R<sup>3</sup> er hydrogen eller halogen;

R<sup>4</sup> er C<sub>1-6</sub>alkyl;

R<sup>5</sup> er hydrogen;

R<sup>6</sup> er hydrogen;

R<sup>8</sup> er -C<sub>m</sub>H<sub>2m</sub>- , C<sub>3-7</sub>sykloalkyl-C<sub>m</sub>H<sub>2m</sub>- eller fenyl;

m er 1-6;

eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

18. Forbindelse ifølge et hvilket som helst av kravene 1 til 14, valgt fra

Metyl-(4R)-4-(2-klor-4-fluor-fenyl)-6-[(6-okso-1,3,4,8,9,9a-heksahydropyrazino[1,2-c][1,3]oksazin-2-yl)metyl]-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-4-(2-klor-4-fluor-fenyl)-6-[(4-okso-6,7,9,9a-tetrahydro-1H-pyrazino[2,1-c][1,4]oksazin-8-yl)metyl]-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>R)-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-7-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>S)-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-7-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>S)-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-2-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>R)-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-2-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>R)-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-2-yl)metyl]-4-(2-brom-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4R)-6-[[<sup>a</sup>R)-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-2-yl)metyl]-4-(2-brom-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4S)-6-[[<sup>a</sup>R)-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-2-yl)metyl]-4-(3,4-difluorfenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4R)-4-(2-klor-3-fluor-fenyl)-6-[(6-okso-3,4,7,8,9,9a-heksahydro-1H-pyrido[1,2-a]pyrazin-2-yl)metyl]-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>R)-3-okso-1,2,5,6,8,8a-heksahydroimidazo[1,5-a]pyrazin-7-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>a</sup>S)-3-okso-1,2,5,6,8,8a-heksahydroimidazo[1,5-a]pyrazin-7-yl)metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4R)-6-[[<sup>(8aS)</sup>-3-okso-1,2,5,6,8,8a-heksahydroimidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-brom-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Etyl-(4R)-6-[[<sup>(8aR)</sup>-3-okso-1,2,5,6,8,8a-heksahydroimidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-brom-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>(8aR)</sup>-1,3-diokso-5,6,8,8a-tetrahydroimidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>(8aS)</sup>-1,3-diokso-5,6,8,8a-tetrahydroimidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>(3aS)</sup>-1,1-diokso-2,3,3a,4,6,7-heksahydro-[1,2,5]tiadiazolo[2,3-a]pyrazin-5-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-6-[[<sup>(3aR)</sup>-1,1-diokso-2,3,3a,4,6,7-heksahydro-[1,2,5]tiadiazolo[2,3-a]pyrazin-5-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

3-[<sup>(8aS)</sup>-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

3-[<sup>(8aS)</sup>-7-[(4R)-4-(2-klorfenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2-metyl-propansyre;

3-[<sup>(8aS)</sup>-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2-metyl-propansyre;

3-[<sup>(8aS)</sup>-7-[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

Etyl-(4R)-4-(2-klor-3-fluor-fenyl)-6-[[2-(2-metoksy-1,1-dimetyl-2-okso-etyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-2-tiazol-2-yl-

1,4-dihydropyrimidin-5-karboksylat;  
Metyl-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-2,5,6,8-tetrahydro-1H-imidazo[1,5-a]pyrazin-8a-karboksylat;  
(R)-6-[(S)-2-(4-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremetylester;  
(R)-6-[(S)-2-(4-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;  
(R)-6-[(S)-2-(3-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;  
(R)-6-[(S)-2-(2-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;  
(R)-6-[(S)-2-(3-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremetylester;  
2-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-syklopropyl-3-okso-1,5,6,8-tetrahydroimidazo[1,5-a]pyrazin-8a-yl]eddkisyre;  
2-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-1,5,6,8-tetrahydroimidazo[1,5-a]pyrazin-8a-yl]eddkisyre;  
(R)-6-[(S)-2-(1-karboksy-1-metyl-etyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;  
3-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-3-metyl-butansyre;  
3-[(8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-

dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-3-methyl-butansyre;  
1-[[[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
1-[[[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
3-[(8aS)-7-[[[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-3-methyl-butansyre;  
1-[[[(8aS)-7-[[[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
3-[(2S,8aR)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklobutankarboksylsyre;  
3-[(8aR)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklobutankarboksylsyre;  
3-[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
3-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
3-[(8aS)-7-[[[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
3-[(8aS)-7-[[[(4S)-4-(3-fluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre; og

7-[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-syklopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre.

2-[1-[(8aR)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopropyl]eddiksyre;

2-[1-[(8aR)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopropyl]eddiksyre;

2-[1-[(8aR)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopropyl]eddiksyre;

(1R,2R)-2-[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopentankarboksylsyre;

(1S,2R)-2-[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopentankarboksylsyre;

(1R,2S)-2-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopentankarboksylsyre;

(1S,2S)-2-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]syklopentankarboksylsyre;

4-[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]butansyre;

4-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-butansyre;

4-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-

a]pyrazin-2-yl]-3,3-dimetyl-butansyre;  
(R)-6-[(S)-2-(2-karboksy-etyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[(S)-2-((R)-2-karboksy-1-metyl-etyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[(S)-2-((S)-2-karboksy-1-metyl-etyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[(S)-2-(1-karboksy-syklobutylmetyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremestylester;  
6-[(S)-2-(1-karboksy-syklobutylmetyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-((R)-2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[(S)-2-((1R,3S)-3-karboksy-syklopentyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremestylester;  
(R)-6-[(S)-2-((R)-(S)-3-karboksy-syklopentyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[(S)-2-((1R,3R)-3-karboksy-syklopentyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremestylester;  
(R)-6-[(S)-2-((1R,3R)-3-karboksy-syklopentyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
(R)-6-[2-(4-karboksy-benzyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremestylester;  
(R)-6-[2-(4-karboksy-benzyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-

ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylyreetylester;

2-[2-[7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]etoksy]eddiksyre;

2-[3-[7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]propoksy]eddiksyre;

Metyl-(4R)-4-(2-klor-4-fluor-fenyl)-6-[[2-(5-hydroksy-4,4-dimethyl-pentyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4R)-4-(2-klor-3-fluor-fenyl)-6-[[2-(2-hydroksyethyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

Etyl-(4R)-4-(2-klor-3-fluor-fenyl)-6-[[2-(2-hydroksyethyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;

4-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]sykloheksankarboksylyre;

4-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]sykloheksankarboksylyre;

3-[(8aS)-7-[(4R)-4-(2-klorfenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

2-[[8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]butansyre;

3-[(8aS)-7-[(4S)-5-etoksykarbonyl-4-(3-fluor-2-methyl-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

3-[(8aS)-7-[[4-(4-klorfenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

3-[(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2-metoksy-propansyre;

2-[(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]spiro[3.3]heptan-6-karboksylsyre;

5-[(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]pentansyre;

3-[[<sup>(8aS)</sup>-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklobutankarboksylsyre;

(8R,8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-syklopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-syklopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8R,8aS)-2-syklopropyl-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-2-syklopropyl-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8R,8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-

imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8R,8aS)-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8S,8aR)-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8R,8aS)-2-tert-butyl-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8S,8aR)-2-tert-butyl-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8R,8aS)-2-tert-butyl-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8S,8aR)-2-tert-butyl-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8R,8aS)-2-tert-butyl-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8S,8aR)-2-tert-butyl-7-[[<sup>(4S)</sup>-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
Metyl-(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-2,5,6,8-tetrahydro-1H-imidazo[1,5-a]pyrazin-8a-karboksylat;  
2-[(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-1,1-dimetyl-3-okso-6,8-dihydro-5H-oksazolo[3,4-a]pyrazin-8a-yl]eddkysyre;  
2-[(8aR)-7-[[<sup>(4R)</sup>-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-

dihydropyrimidin-6-yl]metyl]-1,1-dimetyl-3-okso-6,8-dihydro-5H-oksazolo[3,4-a]pyrazin-8a-yl]eddiksyre;

(8S,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-metyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8R,8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-metyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

Metyl-(4R)-6-[(8R,8aS)-2-tert-butyl-8-karbamoyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4R)-6-[(8S,8aR)-2-tert-butyl-8-karbamoyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

3-[(8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-propoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

4-[(8aS)-7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-butansyre;

5-[7-[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]pyridin-2-karboksylsyre;

(S)-6-[(S)-2-(2-karboksy-2,2-difluor-etyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(3,4-difluor-2-metyl-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;

(8R,8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(syklopropylmetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(syklopropylmetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

3-[(8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-(4-metyltaiazol-2-yl)-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

2-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-1-karboksylsyre;

(8R,8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isobutyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isobutyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8R,8aR)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-8-karboksylsyre;

(8S,8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-8-karboksylsyre;

Etyl-(4R)-6-[[<sup>(8R,8aS)</sup>-2-tert-butyl-8-(hydroksymetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Etyl-(4R)-6-[[<sup>(8S,8aR)</sup>-2-tert-butyl-8-(hydroksymetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Etyl-(4R)-6-[[<sup>(8aR)</sup>-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat; og

Etyl-(4R)-6-[[<sup>(8aS)</sup>-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

(8R,8aS)-7-[[<sup>(4R)</sup>-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(2,2-difluoretyl)-3-okso-5,6,8,8a-tetrahydro-1H-

imidazo[1,5-a]pyrazin-8-karboksylsyre;  
 (8S,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-2-(2,2-difluoretyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
 Etyl-(4R)-6-[(8aR)-2-(2-hydroksy-2-metyl-propyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;  
 og           Etyl-(4R)-6-[(8aS)-2-(2-hydroksy-2-metyl-propyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihdropyrimidin-5-karboksylat;  
 eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

19. Forbindelse ifølge et hvilket som helst av kravene 1 til 15 eller 17, valgt fra  
 3-[(8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
 3-[(8aS)-7-[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihdropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
 (R)-6-[(S)-2-(4-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremetylester;  
 (R)-6-[(S)-2-(4-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
 (R)-6-[(S)-2-(3-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreestylester;  
 (R)-6-[(S)-2-(3-karboksy-fenyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremetylester;  
 3-[(8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-

dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-3-methyl-butansyre;  
1-[[[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
1-[[[(8aS)-7-[[[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
1-[[[(8aS)-7-[[[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]metyl]syklopropankarboksylsyre;  
3-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre; og  
3-[(8aS)-7-[[[(4S)-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;  
4-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-butansyre;  
4-[(8aS)-7-[[[(4R)-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-3,3-dimetyl-butansyre;  
(R)-6-[(S)-2-(1-karboksy-syklobutylmetyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyremetylester;  
6-[(S)-2-(1-karboksy-syklobutylmetyl)-3-okso-heksahydro-imidazo[1,5-a]pyrazin-7-ylmetyl]-4-((R)-2-klor-3-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydro-pyrimidin-5-karboksylsyreetylester;  
3-[(8aS)-7-[[[(4S)-5-etoksykarbonyl-4-(3-fluor-2-metyl-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimetyl-propansyre;

(8S,8aR)-7-[(*(4R)*-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-syklopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-2-syklopropyl-7-[(*(4S)*-4-(3,4-difluor-2-metyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[(*(4R)*-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-7-[(*(4S)*-4-(3,4-difluor-2-methyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-isopropyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-2-tert-butyl-7-[(*(4R)*-4-(2-klor-4-fluor-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-2-tert-butyl-7-[(*(4R)*-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8S,8aR)-2-tert-butyl-7-[(*(4S)*-4-(3,4-difluor-2-methyl-fenyl)-5-metoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;

(8R,8aS)-7-[(*(4R)*-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-metyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;


Metyl-(4*R*)-6-[(*(8R,8aS)*-2-tert-butyl-8-karbamoyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;

Metyl-(4*R*)-6-[(*(8S,8aR)*-2-tert-butyl-8-karbamoyl-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-7-yl]metyl]-4-(2-klor-4-fluor-fenyl)-2-tiazol-2-yl-1,4-dihydropyrimidin-5-karboksylat;


4-[(8a*S*)-7-[(*(4R)*-4-(2-klor-4-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-

a]pyrazin-2-yl]-2,2-dimetyl-butansyre;  
(8R,8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(syklopropylmetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
(8S,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(syklopropylmetyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
2-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-6-okso-1,3,4,7,8,8a-heksahydropyrrolo[1,2-a]pyrazin-1-karboksylsyre;  
(8R,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-8-karboksylsyre;  
(8S,8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-3-okso-5,6,8,8a-tetrahydro-1H-oksazolo[3,4-a]pyrazin-8-karboksylsyre;  
(8R,8aS)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(2,2-difluoretyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre; og  
(8S,8aR)-7-[(4R)-4-(2-klor-3-fluor-fenyl)-5-etoksykarbonyl-2-tiazol-2-yl-1,4-dihydropyrimidin-6-yl]metyl]-2-(2,2-difluoretyl)-3-okso-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-8-karboksylsyre;  
eller farmasøytisk akseptable salter eller enantiomerer eller diastereomerer derav.

20. Prosess for fremstilling av en forbindelse ifølge et hvilket som helst av kravene 1 til 19, som omfatter reaksjonen av en forbindelse med formel (A)



med



i tilstedeværelse av en base;

hvor R<sup>1</sup> til R<sup>6</sup>, X, Y, W og n er definert som i et hvilket som helst av kravene 1 til 18.

21. Forbindelse ifølge et hvilket som helst av kravene 1 til 19 for anvendelse som et terapeutisk aktivt stoff.

22. Farmasøytsk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 19 og en terapeutisk inert bærer.

23. Anvendelsen av en forbindelse ifølge et hvilket som helst av kravene 1 til 19 for fremstilling av et medikament for behandling eller profylakse av hepatitt B-virusinfeksjon.

24. Forbindelse ifølge et hvilket som helst av kravene 1 til 19 for anvendelse ved behandling eller profylakse av hepatitt B-virusinfeksjon.